Product Review – Subcutaneous normal human immunoglobulin

As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of subcutaneous normal human immunoglobulin (Hizentra).

This review discusses pharmacological properties, dosage and administration, efficacy and tolerability, Chronic Inflammatory Demyelinating Polyneuropathy, PID, and Secondary symptomatic hypogammaglobulinaemia.

It also provides commentary and recommendations from Dr Mary Ann Anderson and Associate Professor Arman Sabet.

Please login below to download this issue (PDF)

Subscribe